Abeona Therapeutics Inc. (NASDAQ: ABEO) is -4.89% lower on its value in year-to-date trading and has touched a low of $1.35 and a high of $5.19 in the current 52-week trading range. The ABEO stock was last observed hovering at around $3.11 in the recent trading session, with the current gains setting it 0.21%.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $3.32, the stock is 12.34% and 13.86% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.61 million and changing 6.63% at the moment leaves the stock 20.36% off its SMA200. ABEO registered -31.80% loss for a year compared to 6-month gain of 7.24%. The firm has a 50-day simple moving average (SMA 50) of $3.0209 and a 200-day simple moving average (SMA200) of $2.7613.
The stock witnessed a 7.24% gain in the last 1 month and extending the period to 3 months gives it a 48.80%, and is 10.87% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.79% over the week and 6.85% over the month.
Distance from 52-week low is 145.64% and -36.10% from its 52-week high.
Abeona Therapeutics Inc. (ABEO) Analyst Forecasts
Abeona Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at -$0.17.The EPS is expected to shrink by -27.10% this year.
Abeona Therapeutics Inc. (ABEO) Top Institutional Holders
130 institutions hold shares in Abeona Therapeutics Inc. (ABEO), with 14.91M shares held by insiders accounting for 17.82% while institutional investors hold 80.80% of the company’s shares. The shares outstanding are 92.64M, and float is at 67.23M with Short Float at 4.23%. Institutions hold 66.40% of the Float.
The top institutional shareholder in the company is Great Point Partners LLC with over 7.21 million shares valued at $15.15 million. The investor’s holdings represent 8.62% of the ABEO Shares outstanding. As of Mar 30, 2020, the second largest holder is Adage Capital Partners GP L.L.C. with 5.5 million shares valued at $11.55 million to account for 6.57% of the shares outstanding. The other top investors are Wellington Management Company, LLP which holds 5.44 million shares representing 6.50% and valued at over $11.43 million, while Blackrock Inc. holds 4.38% of the shares totaling 3.67 million with a market value of $7.7 million.
Abeona Therapeutics Inc. (ABEO) Insider Activity
A total of 11 insider transactions have happened at Abeona Therapeutics Inc. (ABEO) in the last six months, with sales accounting for 1 and purchases happening 10 times. The most recent transaction is an insider sale by CARR EDWARD, the company’s Chief Accounting Officer. SEC filings show that CARR EDWARD sold 6,446 shares of the company’s common stock on Mar 19 at a price of $1.81 per share for a total of $11667.0. Following the sale, the insider now owns 13554.0 shares.
Abeona Therapeutics Inc. disclosed in a document filed with the SEC on Dec 24 that Buono Stefano (Director) bought a total of 200,000 shares of the company’s common stock. The trade occurred on Dec 24 and was made at $2.50 per share for $0.5 million. Following the transaction, the insider now directly holds 0.27 million shares of the ABEO stock.
Abeona Therapeutics Inc. (ABEO): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 1.71% up over the past 12 months. Ironwood Pharmaceuticals Inc. (IRWD) is -1.82% down on the 1-year trading charts. Short interest in the company’s stock has fallen -43.51% from the last report on May 14, 2020 to stand at a total of 4.09 million short shares sold with a short interest ratio of 3.1.